Recent News

• 09.15.2025 - Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
• 09.15.2025 - Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
• 09.09.2025 - Trevor Allred
• 09.09.2025 - Trevor Allred
• 09.08.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.08.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.04.2025 - Cantor Global Healthcare Conference
• 09.04.2025 - Cantor Global Healthcare Conference
• 09.03.2025 - Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
• 09.03.2025 - Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

Recent Filings

• 09.03.2025 - 8-K Current report
• 09.03.2025 - EX-99.1 EX-99.1
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]